$COCP
Cocrystal Pharma, Inc.

2024 Q3 Form 10-Q Financial Statement

#000149315224031877 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.800M $1.140M
YoY Change -2.7% -25.88%
% of Gross Profit
Research & Development $3.242M $4.308M
YoY Change -22.7% 53.8%
% of Gross Profit
Depreciation & Amortization $30.00K $33.00K
YoY Change -40.0% -29.79%
% of Gross Profit
Operating Expenses $5.042M $5.448M
YoY Change 13.48% 25.56%
Operating Profit -$5.042M -$5.448M
YoY Change 13.48% 25.56%
Interest Expense $103.0K $105.0K
YoY Change -132.19% -175.0%
% of Operating Profit
Other Income/Expense, Net $103.0K $105.0K
YoY Change -62.95% -39.31%
Pretax Income -$4.939M -$5.343M
YoY Change 18.44% 28.25%
Income Tax
% Of Pretax Income
Net Earnings -$4.939M -$5.343M
YoY Change 18.58% 28.25%
Net Earnings / Revenue
Basic Earnings Per Share -$0.49 -$0.53
Diluted Earnings Per Share -$0.49 -$0.53
COMMON SHARES
Basic Shares Outstanding 10.17M shares 10.17M shares
Diluted Shares Outstanding 10.17M shares 10.17M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.02M $18.14M
YoY Change -56.16% -44.04%
Cash & Equivalents $13.10M $18.14M
Short-Term Investments
Other Short-Term Assets $584.0K $440.0K
YoY Change -69.26% -79.39%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $14.26M $19.66M
YoY Change -55.73% -45.02%
LONG-TERM ASSETS
Property, Plant & Equipment $181.0K $211.0K
YoY Change -28.17% -30.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $29.00K $29.00K
YoY Change -36.96%
Other Assets
YoY Change
Total Long-Term Assets $1.977M $1.913M
YoY Change 383.37% 269.31%
TOTAL ASSETS
Total Short-Term Assets $14.26M $19.66M
Total Long-Term Assets $1.977M $1.913M
Total Assets $16.23M $21.57M
YoY Change -50.23% -40.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $859.0K $1.743M
YoY Change 51.23% 67.44%
Accrued Expenses $1.089M $911.0K
YoY Change -22.21% 66.85%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.948M $2.654M
YoY Change 1.25% 67.23%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.582M $1.529M
YoY Change 15190.0%
Total Long-Term Liabilities $1.582M $1.529M
YoY Change 15190.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.948M $2.654M
Total Long-Term Liabilities $1.582M $1.529M
Total Liabilities $3.530M $4.183M
YoY Change 83.47% 161.93%
SHAREHOLDERS EQUITY
Retained Earnings -$330.2M -$325.2M
YoY Change 6.0% 5.83%
Common Stock $342.9M $342.6M
YoY Change 0.21% 0.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.70M $17.39M
YoY Change
Total Liabilities & Shareholders Equity $16.23M $21.57M
YoY Change -50.23% -40.54%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$4.939M -$5.343M
YoY Change 18.58% 28.25%
Depreciation, Depletion And Amortization $30.00K $33.00K
YoY Change -40.0% -29.79%
Cash From Operating Activities -$5.123M -$3.699M
YoY Change 91.16% -33.33%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -5.123M -3.699M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 0.000
Net Change In Cash -5.123M -3.699M
YoY Change 91.16% 136.81%
FREE CASH FLOW
Cash From Operating Activities -$5.123M -$3.699M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$5.123M -$3.699M
YoY Change 91.16% -33.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10174000 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10174000 shares
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1529000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
4183000 usd
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
10000 usd
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
342593000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-325213000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21573000 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18143000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26353000 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1613000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
4875000 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10174000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10174000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10174000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10174000 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
10000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
342288000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-315914000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
17390000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
26384000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31259000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2801000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7258000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6708000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1538000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2348000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2742000 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
5448000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
4339000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5448000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4339000 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
-151000 usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
-140000 usd
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-46000 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
33000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
105000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
173000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-5343000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4166000 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.03
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10065000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10065000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10174000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10174000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9109000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9109000 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
26384000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
157000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3956000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
22585000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
148000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-5343000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
17390000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
39567000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
291000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5189000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
34669000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
34669000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
179000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4000000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4166000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
34682000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
34682000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9299000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9355000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
68000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
96000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
305000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
470000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1408000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-183000 usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-17000 usd
COCP Increase Decrease In Value Added Tax Receivable
IncreaseDecreaseInValueAddedTaxReceivable
187000 usd
COCP Increase Decrease In Value Added Tax Receivable
IncreaseDecreaseInValueAddedTaxReceivable
491000 usd
COCP Decrease Operating Lease Right Of Use Asset
DecreaseOperatingLeaseRightOfUseAsset
178000 usd
COCP Decrease Operating Lease Right Of Use Asset
DecreaseOperatingLeaseRightOfUseAsset
108000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-619000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
445000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-73000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-115000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8202000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8659000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
59000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-59000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
7000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3993000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8210000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4725000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
26428000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
37219000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18218000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
32494000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9299000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8202000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18143000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_843_eus-gaap--UseOfEstimates_zIYQ7UvpiAcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_ztlzK6Vphkac">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation of the Company’s consolidated financial statements in conformance with U.S. GAAP requires the Company’s management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The significant estimates in the Company’s consolidated financial statements relate to the valuation of equity awards and warrant liabilities, recoverability of deferred tax assets, estimated tax credit receivable and estimated useful lives of fixed assets. The Company bases estimates and assumptions on historical experience, when available, and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis, and its actual results may differ from estimates made under different assumptions or conditions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zyt3RBSj65Kj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zMogKs4jQHY1">Concentrations of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash deposited in accounts held at two U.S. financial institutions, which may, at times, exceed federally insured limits of $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20240630_zfcadKq9IQM6" title="Cash FDIC insured amount">250,000</span> for each institution where accounts are held. At June 30, 2024 and December 31, 2023, our primary operating accounts held approximately $<span id="xdx_904_eus-gaap--Cash_iI_pp0p0_c20240630_zm8qvzARdB45" title="Cash">7,536,000</span> and $<span id="xdx_905_eus-gaap--Cash_iI_pp0p0_c20231231_zsXXWnVzBVql" title="Cash">16,322,000</span>, respectively, and our collateral account balance was $<span id="xdx_902_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20240630_zRzN3PRj6qt1" title="Restricted cash">75,000</span> and $<span id="xdx_90D_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20231231_zYe8QBUAvAc9" title="Collateral account balance">75,000</span> at a different institution. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risks thereof.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q2 us-gaap Cash
Cash
7536000 usd
CY2023Q4 us-gaap Cash
Cash
16322000 usd
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
75000 usd
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
75000 usd
CY2023Q4 COCP Tax Credit Receivable
TaxCreditReceivable
786000 usd
CY2024Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
264000 usd
CY2024Q2 COCP Tax Credit Receivable
TaxCreditReceivable
1050000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
555000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
363000 shares
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2082000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2074000 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1871000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1803000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
211000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
271000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
68000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
96000 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1743000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1222000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
156000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
109000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
504000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1691000 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2403000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3022000 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
155000000 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
101000000 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10174000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10174000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10174000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10174000 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
us-gaap Common Stock Voting Rights
CommonStockVotingRights
The holders of common stock are entitled to one vote for each share of common stock held.
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
148000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
179000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
305000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
241000 usd
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
402000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y10M24D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
555000 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
10.40
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y8M12D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
307000 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
16.33
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y9M18D
CY2024Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
2.33
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
555000 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
350000 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
278000 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
484000 shares
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
13000 shares
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
833000 shares
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
847000 shares
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060 pure
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y10M24D
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
178000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
344000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
355000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
365000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
376000 usd
CY2024Q2 COCP Lessee Operating Lease Liability Payments Due Year Five And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter
513000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2131000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
351000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1780000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
251000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
189000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
116000 usd
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001493152-24-031877-index-headers.html Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
0001493152-24-031877-index.html Edgar Link pending
0001493152-24-031877.txt Edgar Link pending
0001493152-24-031877-xbrl.zip Edgar Link pending
cocp-20240630.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex31-3.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
form10-q_001.jpg Edgar Link pending
form10-q_002.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
cocp-20240630_def.xml Edgar Link unprocessable
cocp-20240630_lab.xml Edgar Link unprocessable
cocp-20240630_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cocp-20240630_cal.xml Edgar Link unprocessable